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Itch can be suppressed by painful stimuli, but the
underlying neural basis is unknown. We generated
conditional null mice in which vesicular glutamate
transporter type 2 (VGLUT2)-dependent synaptic
glutamate release from mainly Nav1.8-expressing
nociceptorswas abolished. Thesemice showeddefi-
cits in pain behaviors, including mechanical pain,
heat pain, capsaicin-evoked pain, inflammatory
pain, and neuropathic pain. The pain deficits were
accompanied by greatly enhanced itching, as sug-
gested by (1) sensitization of both histamine-depen-
dent and histamine-independent itch pathways and
(2) development of spontaneous scratching and
skin lesions. Strikingly, intradermal capsaicin injec-
tion promotes itch responses in these mutant
mice, as opposed to pain responses in control litter-
mates. Consequently, coinjection of capsaicin was
no longer able to mask itch evoked by pruritogenic
compounds. Our studies suggest that synaptic
glutamate release from a group of peripheral noci-
ceptors is required to sense pain and suppress
itch. Elimination of VGLUT2 in these nociceptors
creates a mouse model of chronic neurogenic itch.
INTRODUCTION
Itch and pain represent two distinct sensations. Moreover, it has
been long recognized that there is an antagonistic relationship
between pain and itch (Ikoma et al., 2006; Schmelz, 2010). Over
80 years ago, Lewis et al. first reported that itch sensation evoked
by histamine injection in humans can be blocked by electrical
stimuli (Lewis et al., 1927). Other painful stimuli, such as noxious
heat and noxious chemicals (mustard oil or capsaicin), can alsosuppress itch (Brull et al., 1999; Graham et al., 1951; Ward
et al., 1996). Electrophysiological studies show that the firing of
spinal itch relay neuronscanbesuppressedby inputsof pain-pro-
cessing neurons (Andrew andCraig, 2001; Davidson et al., 2009).
Conversely, a blockage of pain can induce or enhance itch. For
example, pain inhibition by anesthetic compounds can enhance
itch evoked by histamine (Atanassoff et al., 1999), and intrathecal
injection of opioid analgesics is often associated with itch side
effects (Ikoma et al., 2006; Schmelz, 2010).
Several theories have been proposed to explain itch suppres-
sion by pain. The population coding hypothesis, also called
selectivity hypothesis, proposes that the senses of itch and
pain are processed along specific neural circuits or labeled lines,
but the activation of pain-sensing fibers can dominantly mask
itch, even if the stimuli activate both pain-sensing and itch-
sensing fibers (Handwerker, 2010; McMahon and Koltzenburg,
1992; Schmelz, 2010; Wood et al., 2009). The existence of
itch-specific neurons was supported initially by electrophysio-
logical studies in humans and cats (Andrew and Craig, 2001;
Schmelz et al., 1997) and subsequently by genetic and cell abla-
tion studies in mice (Liu et al., 2009; Sun and Chen, 2007; Sun
et al., 2009). For example, sensory neurons expressing the
G-protein coupled receptor Mrgpra3, which represent 4%–5%
of neurons in dorsal root ganglia (DRG) (Liu et al., 2008), are
necessary for itch evoked by chloroquine but dispensable for
pain (Liu et al., 2009). Spinal neurons expressing the gastrin-
releasing peptide receptor (GRPR) are also dedicated to itch
(Sun and Chen, 2007; Sun et al., 2009). The spatial contrast
theory, however, proposes that pain and itch can be encoded
without having itch-specific and pain-specific neurons: itch is
evoked when a minority of nociceptive fibers are activated in
a receptive field, whereas pain is evoked when a majority of
fibers are activated (Johanek et al., 2008; LaMotte et al., 2009;
Namer et al., 2008; Schmelz, 2010; Sikand et al., 2009).
However, this view seems to conflict with the actual existence
of itch-specific circuits, as mentioned above.
Thus, the coding of pain versus itch may be best explained by
the population-coding hypothesis that highlights both theNeuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc. 543
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VGLUT2 Is Required for Itch Suppression by Painexistence of itch-specific and pain-specific sensory neurons, as
well as a dominant suppression of itch by pain. However, while
important progress has been made in identifying itch-specific
sensory neurons (Andrew and Craig, 2001; Liu et al., 2009;
Schmelz et al., 1997; Sun and Chen, 2007; Sun et al., 2009),
the neural basis underlying itch suppression by painful stimuli
has not yet been characterized.
Vesicular glutamate transporter type 2 (VGLUT2) and the
related proteins, VGLUT1 and VGLUT3, belong to a family of
transporters that package glutamate into synaptic vesicles and
are necessary for most fast excitatory synaptic transmission in
the vertebrate nervous system (Fremeau et al., 2004). These
three proteins are expressed in a partially overlapping manner
in peripheral sensory neurons in DRG (Brumovsky et al., 2007;
Seal et al., 2009). By generating and analyzing Vglut2 conditional
knockout mice, here we found that VGLUT2-dependent synaptic
glutamate release from mainly Nav1.8-expressing nociceptors
represents a neuronal component that is critical for pain sensa-
tion and itch suppression. Removal of VGLUT2 in these nocicep-
tors leads to (1) marked pain deficits, (2) sensitization of multiple
itch pathways, and (3) spontaneous development of excessive
scratching and skin lesions. Moreover, capsaicin is able to acti-
vate a normally hidden itch pathway in these mutant mice and
fails to suppress itch evoked by pruritogenic compounds. These
studies provide insight into the neural basis underlying an antag-
onistic interaction between pain and itch.
RESULTS
Generation of Vglut2 CKO Mice
In this study, we made Vglut2 conditional knockout mice by
using the Nav1.8Cre transgenic mice made by the Kuner group
(Agarwal et al., 2004). It had been reported that in Nav1.8Cre
transgenic mice, Cre activity is detected in DRG but not in the
central nervous system (CNS) (Agarwal et al., 2004). To further
determine Cre specificity, we crossed Nav1.8Cre mice with
Cre-dependent TauGFP reporter mice (Hippenmeyer et al.,
2005) in which Nav1.8Cre-active neurons were marked by the
expression of green fluorescent protein (GFP) and can be
detected by GFP immunostaining (Figure S1, available online).
A double staining of GFP with the panneural marker SCG10
(Stein et al., 1988) showed that 81.0% (884/1091) of lumbar
DRG neurons expressed GFP. Additional double staining
showed that GFP was expressed in all Nav1.8-expressing
neurons but, surprisingly, also in a small subset of Nav1.8-nega-
tive DRG neurons (Figure S1), which is different from another
Nav1.8Cre line made by the Wood group that drives reporter
expression only in Nav1.8-expressing neurons (Stirling et al.,
2005). We had also crossed Nav1.8Cre with ROSARFP reporter
mice (Madisen et al., 2010), with the resulting heterozygous
mice referred to as ROSARFP;Nav1.8Cre, in which Nav1.8Cre-
active neurons can be directly visualized with the expression of
red fluorescent protein (RFP) without the involvement of immu-
nostaining (Figure S2). As described below, ROSARFP;Nav1.8Cre
mice were used to examine the expression of other markers in
Nav1.8Cre-active DRG neurons.
To determine the distribution of VGLUT2 expression in DRG,
we performed VGLUT2 immunostaining in lumbar DRG of544 Neuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc.ROSARFP;Nav1.8Cre mice. We found that all RFP-expressing,
and thereby Nav1.8Cre-active, neurons coexpressed VGLUT2,
albeit at heterogeneous expression levels (Figure 1A). Eighty-
eight percent and twelve percent of VGLUT2-expressing
neurons are RFP positive (Nav1.8Cre active) and RFP negative
(Nav1.8Cre negative), respectively (Figure 1A).
To make a Vglut2 conditional knockout in the DRG, we
crossed mice carrying a conditional null allele of Vglut2 (Vglut2F)
with Nav1.8Cre transgenic mice (Agarwal et al., 2004; Tong et al.,
2007), with the resulting homozygous conditional knockout mice
(Vglut2F/F;Nav1.8Cre) referred to as CKO mice (Figure S3A). The
Vglut2F/F littermates were referred to as control mice. Consistent
with the observation that 88% of VGLUT2-expressing neurons
are Nav1.8Cre active, VGLUT2 expression was greatly reduced
in CKOmice (Figure S3B). Double staining showed that in control
mice, VGLUT2 expression was expressed in all nonpeptidergic
nociceptors marked by the binding of the isolectin B4
(IB4; Figure 1B) and peptidergic nociceptors marked by the
expression of calcitonin-gene-related peptide (CGRP;
Figure 1C), albeit at various expression levels; in CKO mice,
VGLUT2 expression in these two groups of neuronswas reduced
to 0.88% and 12.3%, respectively (Figure 1). VGLUT2 expres-
sion was detected in 94.2% of TRPV1-expressing neurons in
control mice but reduced to 3.88% in CKO mice (Figure 1D).
Thus, in Vglut2 CKO mice, VGLUT2 expression is eliminated in
a majority of classical nociceptors.
To determine to what degree the expression of VGLUT1 or
VGLUT3 can compensate for the loss of VGLUT2, we examined
VGLUT1 and VGLUT3 expression in wild-type and CKO mice.
Using ROSARFP;Nav1.8Cre fate-mapping mice, we found that
15.7% of RFP-positive (Nav1.8Cre-active) neurons in lumbar
DRG at postnatal day 30 (P30) coexpressed VGLUT1, and these
neurons represent 38.0% of VGLUT1-expressing neurons
(Figure 2A). Additional double staining showed that VGLUT1
expression was detected in 25.5% of CGRP-expressing
neurons, 2.66% of IB4-positive neurons, and virtually no
TRPV1-expressing neurons (Figure 2B). Importantly, the
numbers of VGLUT1-expressing neurons in P30 lumbar DRG
were unchanged between control and Vglut2 CKO mice
(Figure 2C). With VGLUT3-GFP reporter mice, it was shown
that VGLUT3 was expressed in 10% of lumbar DRG neurons
(Seal et al., 2009). However, VGLUT3 was expressed at levels
too low to be detected by our nonradioactive in situ hybridization
(ISH). We then measured VGLUT3 expression levels in lumbar
DRG by quantitative real-time RT-PCR and found that there
was no significant change in CKO mice (data not shown).
Thus, there is no compensatory increase in VGLUT1 or VGLUT3
expression in Vglut2 CKO mice.
Based on these expression analyses, we concluded that
a majority of Nav1.8Cre-active neurons express VGLUT2 but
not VGLUT1 or VGLUT3; glutamate release from these neurons
should be eliminated in Vglut2 CKO mice. Synaptic glutamate
release in the remaining Nav1.8Cre-active neurons was expected
to be attenuated (because of a loss of VGLUT2) but not to be fully
eliminated (because of VGLUT1 and/or VGLUT3 expression).
Finally, synaptic glutamate release from Nav1.8Cre-negative
neurons, representing 19.0% of total DRG neurons, was
unaffected (summarized in Figure 2D).
Figure 1. Distribution of VGLUT2 Expres-
sion in Control and CKO Lumbar DRG
(A) Double staining of VGLUT2 protein (green) and
the RFP reporter (red) on a section through
a lumbar DRG of the RosaRFP;Nav1.8Cre fate-
mapping mice (described in Figure S2). Note
that VGLUT2 was expressed mainly in RFP-posi-
tive (Nav1.8Cre-active) neurons (arrow) but also
in a subset of GFP-negative (Nav1.8Cre-negative)
neurons (arrowhead). Quantitative data are shown
to the right.
(B–D) Double staining of VGLUT2 protein (green)
with IB4 (red) in (B), CGRP (red) in (C), or TRPV1
protein (red) in (D) on sections through P30 lumbar
DRG of control mice (top) and mutant (CKO) mice
(bottom). Quantitative data are shown to the right.
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The loss of VGLUT2 in a large subset of DRG neurons was
expected to cause reduced excitatory glutamatergic transmis-
sion from DRG neurons onto the dorsal spinal cord. To test
this hypothesis, we recorded spontaneous excitatory postsyn-
aptic currents (sEPSCs) from neurons in lamina II ex vivo in
isolated spinal cord slices from control and CKO mice
(Figure 3A). We indeed found that the frequency of sEPSC was
reduced by 47% in CKO mice (4.22 ± 0.63 spikes/s, n = 11) in
comparison with that in control mice (7.86 ± 1.16 spikes/s,Neuron 68, 543–556, Nn = 9, p < 0.05) (Figure 3B). Since
VGLUT2 was eliminated in the DRG but
not in the CNS, the reduction of sEPSC
in mutant dorsal horn neurons should
be caused exclusively by an impairment
of excitatory glutamatergic transmission
by VGLUT2-dependent primary sensory
afferents, irrespective of direct or indirect
connections between recorded dorsal
horn neurons and primary sensory fibers.
The synaptic transmission defect was
further supported by a change of c-Fos
induction in specific groups of spinal
neurons after intraplantar injection of
capsaicin (see below).
We next askedwhether the attenuation
of excitatory synaptic transmission led
to molecular and anatomical changes
in DRG and the dorsal spinal cord.
The number of total DRG neurons, deter-
mined by the expression of the pan-
neuronal marker SCG10, and the
numbers of IB4-positive andCGRP-posi-
tive neurons were unchanged in lumbar
DRG between CKO and control mice
(Figure S3), suggesting that the develop-
ment and survival of DRG neurons are
unaffected. Furthermore, calcium-im-
aging studies showed that responses to
capsaicin and histamine by DRGneurons
were unchanged (Figure S4). Lamina-specific projections of IB4-positive, CGRP-positive, and
VGLUT1-positive sensory fibers in the dorsal horn of the spinal
cord were also unaffected (Figure 3C). Furthermore, molecular
identities of dorsal horn neurons were also unaffected (Fig-
ure 3D). For example, expression of somatostatin, which is en-
riched in excitatory neurons in the superficial dorsal horn, and
the expression of dynorphin or enkephalin, which are enriched
in inhibitory neurons, were grossly unaffected in CKO mice in
comparison with control mice (Figure 3D) (Bro¨hl et al., 2008;
Huang et al., 2008; Xu et al., 2008). Thus, the molecular andovember 4, 2010 ª2010 Elsevier Inc. 545
Figure 2. Distribution of VGLUT1 Expression in Lumbar DRG
(A and B) Double staining on lumbar DRG. Arrows indicate coexpression and arrowheads indicate singular VGLUT1 expression. Quantitative data are shown to
the right. (A) Double staining of VGLUT1 protein (green) and the RFP reporter (red) on a lumbar DRG section of the RosaRFP;Nav1.8Cre fate-mapping mice
(described in Figure S2). Note that VGLUT1 was expressed mainly in RFP-negative (Nav1.8Cre-negative) neurons (arrowheads) but also in a small subset of
RFP-positive (Nav1.8Cre-active) neurons (arrow). (B) Double staining of VGLUT1 protein (green) with CGRP mRNA (red, top), IB4 (red, middle), or VGLUT1
mRNA (green) with TRPV1 protein (red, bottom) on sections through wild-type lumbar DRG.
(C) Graph showing the total number of VGLUT1-expressing neurons per set of sections through adult lumbar DRG of control and CKO mice. Note that no differ-
ence in the number of VGLUT1-expressing neurons was detected (control: 470 ± 27; CKO: 468 ± 29; p > 0.05). Error bars represent SEM.
(D) Schematic showing expected loss of VGLUT2-dependent synaptic glutamate release in a subset of Nav1.8Cre-active neurons (Nav1.8Cre-act.) that only
express VGLUT2. Glutamate release was partially or fully retained in a subset of Nav1.8Cre-active neurons that express VGLUT1 and/or VGLUT3 (indicated
as VGLUT1,3) or in Nav1.8Cre-negative neurons (Nav1.8Cre-neg.) that express one or multiple VGLUT proteins (indicated as VGLUT1,2,3).
Neuron
VGLUT2 Is Required for Itch Suppression by Painanatomical features of DRG and dorsal spinal cord neurons are
grossly unaffected in Vglut2 CKO mice.
Impaired Acute and Chronic Pain
We next assessed how pain behaviors were affected in CKO
mice, by using Vglut2F/F littermates as a control. In comparison
with control mice, CKO mice showed similar paw withdrawal546 Neuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc.latencies on a 50C hot plate but increased latency at 52C
and 55C (Figure 4A). We also observed a small but significant
increase in withdrawal latencies in the Hargreaves radiant heat
test (Figure 4B). Increased heat pain deficit at higher tempera-
tures is analogous to the mutant phenotype seen in TRPV1 null
mice (Caterina et al., 2000; Davis et al., 2000). Consistently,
acute pain induced by capsaicin injection, which is TRPV1
Figure 3. Attenuation of Excitatory Synaptic Transmission and Unchanged Molecular or Anatomical Features in CKO Mice
(A) sEPSCs recorded from neurons in lamina II of superficial dorsal horn of control (left) and CKO mice (right).
(B) The frequency of sEPSC was reduced by 47% in CKO mice (4.22 ± 0.63 spikes/s, n = 11) in comparison with that in control mice (7.86 ± 1.16 spikes/s, n = 9,
*p < 0.05). Error bars represent SEM.
(C) Double staining of IB4 (red) and CGRP (green) (top) and immunostaining of VGLUT1 (bottom) on P30 dorsal horn sections of control and CKO mice.
(D) ISH with the indicated probes on sections through P30 lumbar (L4-L5) dorsal horn of control and CKO mutant mice.
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VGLUT2 Is Required for Itch Suppression by Paindependent (Caterina et al., 2000; Davis et al., 2000), was again
markedly impaired in CKO mice (see below).
The withdrawal threshold in response to von Frey filaments
was unchanged in CKO mice (Figure 4C), implying that pain
evoked by light noxious mechanical stimuli remains intact. In
contrast, responses to intense noxious mechanical stimuli deliv-
ered by the Randall-Selitto apparatus were markedly attenuated
(Figure 4D).
We next examined two types of chronic pain: inflammatory
and neuropathic. Inflammatory pain was induced by intraplan-
tar injection of complete Freund’s adjuvant (CFA). CFA-induced
mechanical hypersensitivity, measured by reduced mechanical
threshold in eliciting painful withdrawal responses, was signifi-
cantly attenuated in CKO mice (Figure 4E). CFA-induced heat
hypersensitivity, measured by reduced latency in response to
radiant heat, was largely abolished in CKO mice (Figure 4F).
To assess neuropathic pain, we used the spared nerve injury
(SNI) model (Decosterd and Woolf, 2000). In control mice,
SNI caused a profound mechanical hypersensitivity, as indi-
cated by a marked reduction in withdrawal threshold in
response to mechanical stimuli (Figure 4G). Such SNI-inducedmechanical hypersensitivity was largely abolished in CKO mice
(Figure 4G).
Thus, a loss of VGLUT2-dependent synaptic glutamate
release from Nav1.8Cre-active neurons results in deficits in
a range of acute and chronic pain, including intense mechanical
pain, intense heat pain, capsaicin-induced spontaneous pain
(see below), CFA-induced inflammatory pain, and SNI-induced
neuropathic pain.
Sensitization of Multiple Itch Pathways in CKO Mice
The most noticeable mutant phenotype was that by the time
Vglut2 CKO mice reached two months old, a vast majority of
them had developed skin lesions (Figure 5A). The lesions
were most frequently observed around the neck and ears of
mice with brown hairs but also in other parts of the body. In
contrast, none of the control mice showed such lesions (data
not shown). We postulated that the skin lesions were caused
by itch-induced scratches. Therefore, we monitored sponta-
neous scratching at the time when CKO mice showed the
earliest sign of hair loss. We found that CKO mice showed
6-fold more spontaneous scratch bouts than control littermatesNeuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc. 547
Figure 4. Pain Deficits in Vglut2 CKO Mice
(A) Hot plate assay.While no statistically significant difference between control
and CKOmice was observed at 50C (control, n = 8, 17.5 ± 2.0 s; CKO, n = 11,
22.2 ± 1.8 s; p > 0.05), a significant delay in response in CKO versus control
mice was observed at both 52C (control, n = 8, 13.2 ± 0.7 s; CKO, n = 9,
19.7 ± 1.0 s; *p < 0.05) and 55C (control, n = 8, 8.4 ± 0.8 s; CKO, n = 9,
13.4 ± 1.2 s; **p < 0.01).
(B) The Hargreaves radiant heat test. CKO mice showed a delay in withdrawal
latency (control, n = 9, 8.6 ± 0.4 s; CKO, n = 12, 10.0 ± 0.3 s; *p < 0.05).
(C) The von Frey assay. No difference in withdrawal thresholds (control, n = 6,
0.27 ± 0.03 g; CKO, n = 9, 0.29 ± 0.04 g; p > 0.05).
(D) The Randall-Selitto assay. CKO mice showed higher resistance to noxious
mechanical stimulation (control, n = 9, 65 ± 5 g; CKO, n = 11, 115 ± 7 g;
***p < 0.001).
(E and F) CFA-induced inflammatory pain. (E) Mechanical sensitivity (von Frey).
While control animals show a strong drop inwithdrawal threshold with von Frey
filaments after CFA injection (ANOVA; n = 6; p < 0.001), CKO mice showed no
such significant decrease (ANOVA; n = 8; p > 0.05). Importantly, a strong differ-
ence was observed between control and CKO mice (p < 0.01, two-way
repeated ANOVA). (F) Thermal sensitivity (Hargreaves). Similar to the mechan-
ical sensitivity, control animals showed a strong drop in withdrawal threshold
after CFA injection (ANOVA; n = 6; p < 0.001), while CKO mice showed no
Neuron
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548 Neuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc.(Figure 5B). In other words, excessive scratching preceded the
development of overt skin lesions.
To determine whether itching pathways were sensitized in
Vglut2 CKO mice, we injected low dosages of pruritogenic
agents and monitored scratching responses. The experiments
were done on 1-month-old mice; at this age, most CKO mice
had not yet developed excessive spontaneous scratching
behavior (Figure 5C–5H). Compound 48/80 activates a hista-
mine-dependent itching pathway (Sugimoto et al., 1998). Nape
injection of 2 mg of compound 48/80, as opposed to 100 mg
used in other studies (Sun et al., 2009), induced 2-fold increase
in scratching responses in CKO mice from that in control mice
(Figure 5C). Injection of 10 mg of compound 48/80 also induced
more scratching in CKO mice (Figure 5D). The protease-acti-
vated receptor 2 (PAR2) is a G-protein coupled receptor and
activates a histamine-independent itch pathway (Shimada
et al., 2006; Tsujii et al., 2008). Injection of a low dosage (20 mg
as opposed to 100 mg [Sun et al., 2009]) of the PAR2 agonist
SLIGRL-NH2 induced modest scratching responses in control
mice but induced 3-fold more scratch bouts in CKO mice
(Figure 5E). A serotonin derivative, a-Me-5-HT, evokes pure itch-
ing responses in mice (Imamachi et al., 2009). Injection of 30 mg
of a-Me-5-HT also induced more scratching responses in CKO
mice (841 bouts) than in control mice (377 bouts) (Figure 5F).
There was an exception; chloroquine, a compound used to treat
malaria in humans, evoked histamine-independent itch through
activating Mrgpra3 (Liu et al., 2009). We found that chloroquine
evoked similar degrees of scratching responses in Vglut2 CKO
mice and in control littermates at both low and high dosages
(Figure 6G and 6H). These observations suggested that the
loss of VGLUT2 in Nav1.8Cre-active neurons in CKOmice results
in sensitization of multiple, but not all, itch pathways.
Capsaicin Evokes Itch in CKO Mice
Capsaicin activates the TRPV1 transient receptor potential ion
channel, and capsaicin-responsive neurons are essential for
the senses of both pain and itch (Basbaumet al., 2009; Imamachi
et al., 2009; Liu et al., 2009; Lynn, 1992; Shim and Oh, 2008;
Simone et al., 1989). To determine how capsaicin-evoked pain
or itch was affected in CKO mice, we used a recently developed
behavioral assay that clearly distinguishes pain versus itch:
intradermal capsaicin injection in the cheek induces pain-indica-
tive wiping by the forelimb, whereas injection of itching
compounds in the cheek induces scratching by the hind limb
(Shimada and LaMotte, 2008). Again, 1-month-old control and
CKOmicewere used; at this age,mutantmice had not yet shown
any significant difference in baseline scratching or wiping
(Figure 6). After injection of 20 mg of capsaicin, CKO micesignificant decrease (ANOVA; n = 8; p > 0.05). Importantly, a strong difference
was observed between control and CKO mice (p < 0.001, two-way repeated
ANOVA).
(G) SNI-induced neuropathic pain. After SNI, CKO mice showed no significant
decrease over time in withdrawal thresholds after SNI with von Frey filaments
(n = 6, ANOVA, p > 0.05), while control mice showed a strong drop in with-
drawal thresholds (n = 6, ANOVA, p < 0.001). Importantly, a strong difference
was observed between control and CKO (two-way repeated ANOVA,
p < 0.001). Error bars represent SEM.
Figure 5. Itch Sensitization in CKO Mice
(A) Skin lesions in the neck or body of CKO mice.
(B) Increased spontaneous scratch bouts in 2-
month-old CKO mice (control: 56 ± 13; CKO:
371 ± 64; n = 6; **p < 0.01).
(C–H) Itching responses were examined in 1-
month-old control and CKO mice before CKO
mice developed excessive spontaneous scratch-
ing. (C) Increased scratch bouts evoked by
compound 48/80 (2 mg) in CKO mice (control,
from 17 ± 6 baseline scratch bouts to 91 ± 19 after
injections; CKO, from 34 ± 11 to 290 ± 40; n = 6;
**p < 0.01). (D) Increased scratch bouts evoked
by 10 mg of compound 48/80 in CKO mice
(control, from 30 ± 9 baseline scratch bouts to
260 ± 26 after injections; CKO, from 38 ± 9 scratch
bouts to 448 ± 35; n = 8; **p < 0.01). (E) Increased
scratch bouts evoked by PAR2 agonist SLIGRL-
NH2 (20 mg) in CKO mice (control, from 22 ± 4
baseline scratch bouts to 54 ± 15 after injections;
CKO, from 47 ± 14 to 240 ± 48; n = 7; **p < 0.01).
(F) Increased scratch bouts evoked by a-Me-5-HT
(30 mg) in CKO mice (control, from 18 ± 5 scratch
bouts to 377 ± 49; CKO, from 23 ± 11 to 841 ± 78;
n = 3; **p <0.01). (G) Unchanged scratch bouts
evoked by chloroquine (25 mg) in CKO mice
(control, from 17 ± 5 scratch bouts to 126 ± 23;
CKO, from 44 ± 6 to 151 ± 18; n = 4; p > 0.05).
(H) Unchanged scratch bouts evoked by 200 mg
of chloroquine in CKO mice (control, from 16 ± 4
scratch bouts to 328 ± 53; CKO, from 34 ± 13 to
279 ± 79; n = 7; p >0.05). Error bars represent
SEM.
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VGLUT2 Is Required for Itch Suppression by Painexhibited a 56% reduction in the number of wipes compared
to control mice, suggesting an attenuation of capsaicin-evoked
pain (Figure 6A and 6B). More strikingly, capsaicin induced
robust scratching responses in CKO mice, as opposed to
minimal responses in control mice (Figure 6C and 6D). Injection
of capsaicin at a lower dosage (5 mg) also induced more
scratching bouts in CKO mice than control littermates
(Figure 6E), although this low dosage evoked fewer scratching
bouts in comparison with the higher dosage of capsaicinNeuron 68, 543–556, N(Figure 6E versus Figure 6C). This
dramatic behavioral switch suggested
that VGLUT2-dependent synaptic gluta-
mate release is necessary for capsaicin-
evoked pain, and its removal allows
capsaicin to activate a normally masked
itch pathway.
One interpretation of this behavioral
switch is that capsaicin-evoked pain
can dominantly inhibit itch evoked
by capsaicin-sensitive pruriceptors, and
this inhibition is attenuated in CKO
mice. To further explore this possibility,
we asked whether capsaicin can sup-
press itch evoked by a-Me-5-HT, a
potent pruritogenic compound (Fig-
ure 5F) that acts through capsaicin-sensitive neurons (Imamachi et al., 2009). In control mice, cheek
injection of a-Me-5-HT evoked robust scratching responses
(Figure 6F); strikingly, a coinjection of a-Me-5-HT and capsaicin
almost completely inhibited scratching response. In contrast,
a coinjection of a-Me-5-HT and capsaicin in CKO mice still
showed a significant scratching response (Figure 6F), with the
amount of scratch bouts comparable to that evoked by capsa-
icin alone in CKO mice (Figure 6C). These studies suggested
that a strong pain-inducing stimulus such as capsaicin canovember 4, 2010 ª2010 Elsevier Inc. 549
Figure 6. Scratching and Wiping Behaviors
Evoked by Capsaicin
One-month-old control and CKOmice, prior to the
development of excessive spontaneous scratch-
ing in CKO mice, were used.
(A and C) Decreased total wipes in CKO mice (A)
(control, 73 ± 15 wipes; CKO, 32.2 ± 6.7; n = 10;
*p < 0.05) and increased scratching bouts in
CKO mice (C) (control, 3.8 ± 2.0 bouts; CKO,
52.3 ± 11.3; n = 10; **p < 0.01) after capsaicin
(20 mg) injection into the cheek. Prior to capsaicin
injections, there were no differences in baseline
wiping in a 10 min period (control, 1.2 ± 0.4 wipes;
CKO, 1.3 ± 0.7; p > 0.05) or scratching (control,
1.5 ± 0.6 bouts; CKO, 4.3 ± 1.6; p > 0.05).
(B and D) Time course of capsaicin-induced
wiping and scratching (10 to +20 min) in control
mice (blue) and CKO mice (purple). Injections
occurred at time = 0. The mean numbers of bouts
or wipes per minute were plotted.
(E) Increased scratching bouts in CKO mice
(control, 9.9 ± 2.6 bouts; CKO, 33.9 ± 8.7; n = 7;
*p < 0.05) after capsaicin (5 mg) injection. Note
that, compared to (C), lower dosage of capsaicin
evoked fewer scratching bouts in CKO mice.
(F) Capsaicin (20 mg) failed to suppress the
scratching responses evoked by a-Me-5-HT
(10 mg) in CKO mice. Note that in control mice,
itch evoked by injection of a-Me-5-HT (10 mg)
was completely suppressed by coinjection of
capsaicin (20 mg), with scratch bouts reduced
from 112.5 ± 25.4 scratch bouts (a-Me-5-HT
alone) to 3.4 ± 1.6 (a-Me-5-HT plus capsaicin)
(n = 5; *p < 0.05). In CKO mice, however, coinjec-
tion of a-Me-5-HT (10 mg) and capsaicin (20 mg)
still caused significant scratching responses
(49.8 ± 11.9 scratch bouts; n = 5; *p < 0.05), which
is comparable to that evoked by singular injection
of capsaicin (20 mg) in CKO mice.
Error bars in (A), (C), (E), and (F) represent SEM.
The abbreviation Caps. means capsaicin.
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this pain-induced itch inhibition is markedly attenuated in CKO
mice.Loss of VGLUT2 in Mrgpra3-Expressing
and GRP-Expressing Neurons in Vglut2 CKO Mice
The enhanced or normal itching responses seen in Vglut2 CKO
mice suggested that VGLUT2 expression in Nav1.8Cre-active
sensory neurons is dispensable for itch. To further look into
this issue, we examined how VGLUT2 expression was affected
in established or putative pruriceptors. Mrgpra3-expressing pru-
riceptors mediate itch evoked by chloroquine (Liu et al., 2009).
We found that these pruriceptors expressed VGLUT2
(Figure 7A), but not VGLUT1 (Figure 7B), in control mice, and
VGLUT2 expression in these neurons was eliminated in Vglut2
CKO mice (Figure 7A). Sensory neurons expressing the
gastrin-releasing peptide (GRP) are putative pruriceptors (Sun
and Chen, 2007). In control mice, GRP was expressed at high
levels in a subset of small diameter neurons (Figure 7C, arrows),
as reported previously (Sun and Chen, 2007). Low levels of GRP550 Neuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc.expression were detected in many small and large DRG neurons
(Figure 7C, arrowheads), consistent with a more recent report
(Liu et al., 2009). In GRPhigh neurons, VGLUT2 expression was
detected in control mice but was eliminated in Vglut2 CKO
mice (Figure 7C, arrows). Again, no VGLUT1 expression was
detected in GRPhigh neurons (Figure 7D). With enhanced or unaf-
fected itching responses observed in Vglut2 CKO mice, these
data suggest that under the Vglut2 CKO genetic background,
glutamate release from Mrgpra3-expressing and GRPhigh
neurons appears to be dispensable for itch.A Change in Spinal Neuron Activation after Intraplantar
Capsaicin Injection in Vglut2 CKO Mice
Spinal inhibitory neurons have recently been suggested to
play a role in preventing itch sensitization (Ross et al., 2010). It
has also been known for a while that noxious stimuli, such as
intraplantar capsaicin injection, were able to activate spinal
inhibitory neurons (Binshtok et al., 2007; Zou et al., 2002). We
therefore asked whether such activation was affected in Vglut2
CKO mice. We used the induction of c-Fos to identify
Figure 7. Loss of VGLUT2 and Lack of
VGLUT1 in Mrgpra3-Expressing Neurons
and GRPhigh DRG Neurons
(A and C) Double staining of VGLUT2 protein
(green) with Mrgpra3 mRNA (red) in (A) or with
GRP (red) in (C) on sections through control (top)
and CKO (bottom) lumbar DRGs. Arrows and
arrowheads in (C) indicate neurons with high and
low levels of GRP expression, respectively. Note
that in control mice, Mrgpra3 or GRPhigh was
coexpressed with VGLUT2. In CKO mice,
VGLUT2 expression was eliminated in all
Mrgpra3-expressing (A) or GRPhigh neurons (C,
arrows), whereas a subset of GRPlow neurons re-
tained VGLUT2 (C, arrowheads). Quantitative
data are shown to the right.
(B and D) Double staining of VGLUT1 protein
(green) with Mrgpra3 mRNA (red) in (B) or with
GRP (red) in (D) on sections through lumbar
wild-type DRG. Note that VGLUT1 was not ex-
pressed in GRPhigh neurons (D, arrows). Quantita-
tive data are shown to the right.
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et al., 1987; Zou et al., 2002). Previous studies showed that
spinal inhibitory neurons can be identified by the expression of
a set of neuropeptides, including neuropeptide Y (NPY) and
enkephalin (ENK) (Bro¨hl et al., 2008; Huang et al., 2008; Xu
et al., 2008). We found that, after capsaicin injection in hindpaw,
c-Fos expression was detected in 40.1% of NPY-expressing
neurons at the ipsilateral side of control mice but reduced to
11.9% in Vglut2 CKO mice (Figure 8A), a 70.3% reduction.
The reduction of c-Fos-positive neurons was not due to a loss
of NPY-expressing neurons per se, as suggested by the normal
numbers of NPY-expressing neurons in CKO versus control
mice (data not shown). Interestingly, c-Fos induction in ENK-ex-
pressing neurons was unaffected in CKO mice (Figure 8B).
These data suggest that VGLUT2-dependent synaptic gluta-
mate release from Nav1.8Cre-active neurons is required for
capsaicin to activate a specific (NPY-expressing) subset of
spinal inhibitory neurons.Neuron 68, 543–556, NGRPR-expressing spinal neurons are
required to process itching information
(Sun et al., 2009). With the finding that
capsaicin evokes itch, rather than pain,
in CKO mice, we next asked whether
capsaicin injection could differentially
activate GRPR-expressing neurons in
control versus CKO mice. We found
that after intraplantar capsaicin injec-
tion, there was indeed a significant,
albeit modest, increase of c-Fos induc-
tion in GRPR-expressing neurons from
18.5% ± 0.4% in control mice to
27.2% ± 1.5% in CKO mice (p < 0.05),
a 47% increase (Figure 8C). All together,
these studies show that upon removal
of VGLUT2 in Nav1.8Cre-active neurons,capsaicin on one hand fails to activate NPY-expressing spinal
inhibitory neurons but, on the other hand, causes an increase
of activation of GPRP-expressing spinal itch relay neurons.
DISCUSSION
VGLUT2-Dependent Glutamate Release from DRG
Neurons Is Necessary for Acute and Chronic Pain
In this study, we have generated Vglut2 CKO mice in which
Vglut2 was removed from Nav1.8Cre-active DRG neurons.
The loss of VGLUT2 in these neurons leads to impaired glutama-
tergic transmission, as indicated by reduced sEPSC frequency
in postsynaptic dorsal horn neurons, although additional
electrophysiological recording is needed to determine exact
deficits in synaptic transmission in these mice. Behavioral
studies show that VGLUT2-dependent glutamate release from
Nav1.8Cre-active DRG neurons is required to sense a range of
acute and chronic pain, including intense mechanical pain,ovember 4, 2010 ª2010 Elsevier Inc. 551
Figure 8. Changes of c-Fos Induction in Spinal Neurons after Intradermal Capsaicin Injection in the Hindpaw
(A) Transverse sections through dorsal spinal cord at L4-L5 levels of P30 control mice and CKO littermates after capsaicin injection into one hindpaw. Double
staining of c-Fos protein by immunostaining (green) and NPY mRNA by ISH was shown. The bright-field ISH signal (left) was converted into pseudofluorescent
signal (red, middle and right). Arrows indicate colocalization of NPY and c-Fos, and arrowheads indicate singular NPY expression. (Right) Graph shows the
percentage of NPY-expressing neurons that coexpressed c-Fos in the ipsilateral superficial spinal cords of P30 control (open bars) and CKO (gray bars)
mice. Error bars represent SEM. Note that c-Fos induction in NPY-expressing neurons was reduced in CKO mice, from 40.1% ± 3.5% in control mice to
11.9% ± 2.4% in CKO mice (***p < 0.001).
(B and C) are the same as in (A), except that NPY expression was replaced by that of ENKmRNA in (B) and GRPRmRNA in (C). Note that c-Fos induction in ENK-
expressing neurons in the ipsilateral superficial spinal cords after capsaicin injection was unchanged (11.5% ± 1.6% in control mice and 10.9% ± 1.1% in CKO
mice, p > 0.05). In contrast, c-Fos induction in GRPR-expressing neurons was increased in CKO mice, from 18.5% ± 0.4% in control mice to 27.2% ± 1.5% in
CKO mice (*p < 0.05).
The abbreviation Ipsi means ipsilateral to the injection side. Error bars represent SEM.
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VGLUT2 Is Required for Itch Suppression by Paincapsaicin-evoked pain, intense heat pain, and inflammatory and
neuropathic pain. It has been previously reported that ablation of
Nav1.8-expressing neurons causes similar deficits in mechan-
ical and inflammatory pain but, surprisingly, without affecting
neuropathic pain or heat pain (Abrahamsen et al., 2008). How
could we explain the deficits in neuropathic and heat pain after
the loss of VGLUT2 in Nav1.8Cre-active neurons? This discrep-
ancy could be caused by the use of two different Nav1.8Cre
mice. The Nav1.8Cre mice used for cell ablation were made by
the knockin strategy (Abrahamsen et al., 2008) and drove
reporter expression that matches Nav1.8 expression in DRG
(Stirling et al., 2005). However, the Nav1.8Cre mice used in this
study were made through a transgenic approach (Agarwal
et al., 2004) and drove reporter expression not only in all
Nav1.8-expressing neurons but also in a small subset of
Nav1.8-negative neurons (Figure S1). It is possible that the trans-
genic approach might drive Cre expression at higher levels than
the knockin approach, such that neurons normally expressing
low levels of Nav1.8 might contain sufficient Cre activity.552 Neuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc.The loss of VGLUT2 expression in these extra Nav1.8-negative
neurons in Vglut2 CKOmice might then contribute to the impair-
ment of neuropathic and heat pain. Alternatively, compensatory
mechanisms may develop after ablation of Nav1.8-expressing
neurons but not after removal of VGLUT2.
Neuropathic pain is also impaired in conventional Vglut2
heterozygous null mice (Leo et al., 2009; Moechars et al.,
2006). Because VGLUT2 is broadly expressed in the CNS,
including the dorsal horn of the spinal cord, we cannot be certain
of the underlying cellular basis of neuropathic pain deficit in
those heterozygous null mice. By analyzing Vglut2 CKO mice,
we have now clearly shown that VGLUT2-dependent synaptic
glutamate release fromDRG neurons is essential for neuropathic
pain; this association is also consistent with the report that
VGLUT2 expression is elevated in a subset of nociceptors
following nerve injury (Brumovsky et al., 2007).
VGLUT3-expressing DRG neurons represent low-threshold
mechanoreceptors (Seal et al., 2009). Interestingly, mice lacking
Vglut3 also show a partial defect in sensing intense mechanical
Neuron
VGLUT2 Is Required for Itch Suppression by Painpain and a marked deficit in developing persistent mechanical
hypersensitivity following inflammation or nerve injury (Seal
et al., 2009), suggesting that glutamate release from both
VGLUT3-expressing and VGLUT2-expressing neurons is
involved in sensing mechanical pain. Meanwhile, the expression
patterns of VGLUT1, VGLUT2, and VGLUT3 in DRG neurons
could explain why inflammatory heat hypersensitivity, which is
known to be dependent on TRPV1 (Caterina et al., 2000; Davis
et al., 2000), is abolished in Vglut2 CKO mice but not in Vglut3
mutant mice (Seal et al., 2009). Most TRPV1-expressing neurons
show detectable expression of VGLUT2 (Figure 1) but not
VGLUT1 (Figure 2) or VGLUT3 (Seal et al., 2009). In Vglut2
CKO mice, only 4% of TRPV1-expressing neurons retain
VGLUT2 expression. In other words, excitatory glutamatergic
synaptic transmission is eliminated from most TRPV1-express-
ing neurons in Vglut2 CKO mice, which may render them func-
tionally silent, thereby explaining the impaired inflammatory
heat hyperalgesia in these mice.
VGLUT2-Dependent Glutamate Release from
Nav1.8Cre-Active Neurons Is Required to Suppress Itch
Our studies provide insight into the coding of pain versus itch by
showing that VGLUT2-dependent glutamate release from
Nav1.8Cre-active peripheral nociceptors represents a neuronal
component that is required to sense pain and suppress itch.
Removal of this component leads to (1) marked pain deficits,
(2) sensitization of both histamine-dependent and histamine-
independent itch pathways, (3) spontaneous development of
excessive scratching and eventual skin lesions, (4) a failure of
capsaicin to dominantly mask a strong itch signal, and (5) direct
paradoxical promotion of itch by capsaicin. Our studies also
suggest that neurons that retain glutamate release in
Vglut2 CKO mice, including Nav1.8Cre-negative neurons plus
Nav1.8Cre-active neurons that express VGLUT1 and/or VGLUT3,
are insufficient to prevent itch sensitization, even though they
are sufficient to mediate light mechanical pain (measured by
von Frey assay) and light heat pain (measured by a hot plate
at 50C).
Our studies raise an intriguing question regarding the role of
synaptic glutamate release from peripheral pruriceptors in pro-
cessing itching information. In Vglut2 CKO mice, VGLUT2 was
eliminated in 81% of DRG neurons. The loss was not just
confined to pain-sensing neurons, but also occurred in
Mrgpra3-expressing pruriceptors and in putative pruriceptors
marked by GRPhigh expression (Figure 7) (Liu et al., 2009;
Sun and Chen, 2007; Sun et al., 2009). Moreover, Mrgpra3-ex-
pressing and GRPhigh neurons do not express VGLUT1
(Figure 7) and may also not express VGLUT3 since most of
these neurons coexpressed CGRP (Sun and Chen, 2007)
(data not shown), and CGRP-expressing neurons do not
express VGLUT3 (Seal et al., 2009). With the loss of VGLUT2
and a lack of VGLUT1 and VGLUT3 expression in these estab-
lished and putative pruriceptors, it is surprising to observe that
itch evoked by a range of pruritogenic compounds is either
enhanced or unaffected in Vglut2 CKO mice, including chloro-
quine-evoked itch that is mediated by Mrgpra3-expressing
pruriceptors. We envision the following two possibilities. First,
glutamate release from pruriceptors might be dispensable foritch. In other words, pruriceptors may use other transmitters
such as GRP to mediate itch. Consistent with this, intrathecal
injection of GRP is sufficient to evoke scratching response
and histamine-independent itch is markedly impaired in
GRPR mutant mice (Sun and Chen, 2007). Alternatively, gluta-
mate release from pruriceptors may normally act to remove
tonic itch inhibition by pain-processing neurons (Andrew and
Craig, 2001). In Vglut2 CKO mice, the loss of pain may have
already removed such inhibition; as a result, glutamate release
from pruriceptors becomes dispensable for the transmission of
itching information.
How do the pain loss and itch sensitization observed in Vglut2
CKO mice fit into current itch theories? The spatial contrast
hypothesis (Johanek et al., 2008; Namer et al., 2008; Schmelz,
2010) proposes that itch is coded when a small subset of noci-
ceptor fibers is activated in a receptive field, whereas pain is
encoded when more nociceptor fibers are activated. The loss
of VGLUT2 in 81% of DRG neurons in Vglut2 CKO mice will
certainly lead to a great reduction in the density of functional
nociceptor fibers in the skin, and, according to this theory,
such reduction should result in enhanced itching. However, the
argument of the spatial contrast theory that pain and itch can
be coded without having pain-specific and itch-specific fibers
conflicts with the actual existence of itch-specific sensory
neurons, such as Mrgpra3-expressing DRG neurons and
GRPR-expressing spinal neurons (Andrew and Craig, 2001;
Liu et al., 2009; Schmelz et al., 1997; Sun and Chen, 2007; Sun
et al., 2009). Moreover, a reduction in density of functional noci-
ceptor fibers in the skin is not automatically linked with itch
sensitization. For example, ablation of Mrgprd-positive polymo-
dal nociceptors that densely innervate the skin epidermis has no
impact on itch (Imamachi et al., 2009; Rau et al., 2009; Zylka
et al., 2005). Consistently, in Vglut2 CKO mice, a lower dosage
of capsaicin, which is supposed to activate fewer capsaicin-
sensitive fibers and should enhance itch according to the spatial
contrast hypothesis, actually causes reduced scratching
responses in comparison with a higher dosage of capsaicin
(Figure 6).
Thus, with increasing evidence arguing against the spatial
contrast theory, several investigators suggested that the coding
of pain versus itch may be best explained by the population-
coding hypothesis, which emphasizes both the existence of
itch-specific and pain-specific neural components and the
dominant suppression of itch by pain (Handwerker, 2010;
McMahon and Koltzenburg, 1992; Wood et al., 2009). According
to this hypothesis, VGLUT2-dependent glutamate release from
Nav1.8Cre-active DRG neurons should represent a neural
component that is necessary for pain sensation and itch
suppression. For example, in the absence of this component in
Vglut2 CKO mice, a coinjection of a strong pain-inducing
compound (capsaicin) is no longer able to mask itch evoked
by a strong pruritogenic compound (Figure 6). Moreover,
because many itch-sensing neurons respond to capsaicin
(Imamachi et al., 2009; Liu et al., 2009; Lynn, 1992; Shim and
Oh, 2008), the loss of pain-induced inhibition of itch may explain
why capsaicin is able to activate a normally hidden itch path-
way in these mutant mice (Figure 6). The enhanced itching
responses observed in Vglut2 CKO mice do raise the followingNeuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc. 553
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amount of itch in wild-type mice? It should be noted that most
itching compounds (such as histamine) in fact activate both
itch-sensing and pain-sensing neurons (Atanassoff et al.,
1999), and the amount of itch evoked by a pruritogenic
compound is normally attenuated by this pain component. For
example, anesthetic blockage of pain can greatly enhance hista-
mine-evoked itch in humans (Atanassoff et al., 1999). In Vglut2
CKOmice, the loss of pain (and itch inhibition by pain) maymimic
anesthetic treatment in humans, thereby allowing itching
compounds to evoke enhanced responses.
How could painful stimuli suppress itch? It was proposed that
painful stimuli may activate inhibitory neurons in the dorsal spinal
cord, which in turn inhibit itch-processing neurons (Andrew and
Craig, 2001; Davidson et al., 2009; Handwerker, 2010). This
hypothesis is strongly supported by a recent study showing
that Bhlhb5-dependent spinal inhibitory neurons are involved in
itch suppression, and their developmental impairment leads to
sensitization of multiple itch pathways (Ross et al., 2010).
Intriguingly, in Vglut2 CKO mice, capsaicin injection fails to
activate NPY-expressing inhibitory neurons in the spinal cord;
moreover, there is a modest increase in activation of GRPR-ex-
pressing itch relay neurons. Future studies will be warranted to
determine whether capsaicin-responsive pain fibers connect
with NPY-expressing inhibitory neurons to suppress itch and
whether the development of these inhibitory neurons is depen-
dent on Bhlhb5.Concluding Remarks and a Mouse Model
of Neurogenic Itch
Our studies provide insight into the coding of pain versus itch.
First, VGLUT2-dependent glutamate release from Nav1.8Cre-
active neurons is required to sense pain and suppress itch.
The itch sensitization observed in Vglut2 CKO mice is probably
caused by a loss of pain-induced inhibition of itch. Alternatively,
there are two separate populations of VGLUT2-dependent DRG
neurons: one for pain sensation and one for itch suppression.
Second, synaptic glutamate release from established
(Mrgpra3-expressing) and putative (GRPhigh) pruriceptors
appears to be dispensable for the transmission of itching infor-
mation in the Vglut2 CKO background, as indicated by the loss
of VGLUT2 expression and a lack of VGLUT1/3 expression in
these neurons. This observation raises the possibility that pruri-
ceptors may use other transmitters such as GRP tomediate itch.
Third, removal of VGLUT2 from Nav1.8Cre-active DRG neurons
creates a mouse model of chronic neurogenic itch, as indicated
by sensitization of multiple itch pathways and development of
excessive spontaneous scratching and skin lesions. Importantly,
the mutant phenotypes seen in Vglut2 CKO mice are similar to
the symptoms seen in human patients suffering from chronic
itch. In such patients, painful stimuli do not just fail to suppress
itch but, paradoxically, promote itch (Hosogi et al., 2006; Ikoma
et al., 2004; Ishiuji et al., 2008; Schmelz, 2010), exactly analo-
gous to capsaicin-evoked itch seen in Vglut2 CKO mice. The
creation of a mouse model of chronic itch that shares key
features with human patients could be invaluable for future
mechanistic and intervention studies.554 Neuron 68, 543–556, November 4, 2010 ª2010 Elsevier Inc.EXPERIMENTAL PROCEDURES
Animals
The generation of mice carrying the floxed Vglut2 allele, Nav1.8Cre transgenic
mice, RosaRFP mice, and the Tau-lox-STOP-lox-mGFP-IRES-nlsLacZ-neo
mice has been described previously (Agarwal et al., 2004; Hippenmeyer
et al., 2005; Madisen et al., 2010; Tong et al., 2007). For histochemical studies,
mice at P30 were used. For behavioral analyses, 1- to 2-month-oldmutant and
control littermates were used. All behavioral test protocols were approved by
the Institutional Animal Care and Use Committee at Dana-Farber Cancer
Institute.
ISH and Immunostaining
ISH procedures and the probes (CGRP, Nav1.8, SCG10, TrkB, parvalbumin,
somatostatin, dynorphin, and enkephalin) have been described previously
(Chen et al., 2006; Cheng et al., 2004, 2005; Ma et al., 1999; Xu et al., 2008).
Immunohistochemistry (IHC) using rabbit anti-VGLUT1 (1/1000, Swant,
Switzerland), guinea pig anti-VGLUT2 (1/200, Frontier Institute Co., Japan),
chicken anti-GFP (1/1000, Invitrogen, USA), rabbit anti-TRPV1 (1/1000, Ab-
Cam, USA), mouse anti-NF200 (1/200, Sigma, USA), rabbit anti-c-Fos
(1/1000, Santa Cruz, USA), rabbit anti-GRP (1/1000, Immunostar, USA; diluted
in 0.3% of triton x-100, 0.2% of BSA, and 5% of goat serum in PBS), or
IB4-biotin (10 mg/ml, Sigma, USA) was carried out as previously described
(Chen et al., 2006). The ISH/IHC double staining was performed as previously
described (Liu et al., 2008). For RFP/IHC double staining, the RFP fluorescent
signal was directly photographed followed by performance of single IHC. The
fluorescent IHC signals were then merged with the RFP signal.
Cell Counting
L4-L5 lumbar DRG were dissected from two to three pairs of mutant and
control mice. Three to four mutant or control DRG were used to prepare eight
adjacent sections at 12 mm thickness. Each set was processed for immunos-
taining or used for ISH with the gene of interest. Only cells containing nuclei
and showing levels of expression or staining clearly above background were
counted. Averages and standard errors of the mean (SEM) were calculated
and the difference between control and mutant samples was subjected to
a Student’s t test, with p < 0.05 considered significant.
Patch-Clamp Recordings in Spinal Slices
Patch-clamp recording in spinal slices was done as previously reported
(Kawasaki et al., 2008) with L4-L5 from Vglut2F/F; Nav1.8Cre CKO, and
Vglut2F/F control littermates (3–5 weeks old). More detailed procedures are
provided in Supplemental Experimental Procedures.
Surgery
The SNI model for neuropathic pain was performed on adult mice (P30 to P60)
as described for rats (Decosterd and Woolf, 2000) and as we previously did in
mice (Chen et al., 2006). More detailed procedures are provided in Supple-
mental Experimental Procedures.
Pain and Itch Behavioral Test
Vglut2F/F; Nav1.8Cre CKO, and Vglut2F/F control littermates of 1–2 months of
age were used. All pain and itch behavioral tests were performed as previously
described (Chen et al., 2006; Shimada and LaMotte, 2008) with minor modifi-
cations. More detailed procedures are provided in Supplemental Experimental
Procedures.
Double Staining ofCapsaicin-Induced c-Foswith Neuropeptides and
GRPR
One-month-old Vglut2F/F; Nav1.8Cre CKO, and Vglut2F/F control littermates
were given a 2.5 mg/10 ml intraplantar injection of capsaicin under anesthesia.
Two hours later, the L4-L5 spinal cords were dissected and treated as
previously described (Liu et al., 2008). c-Fos immunostaining used 30 min
incubation at room temperature for the primary and secondary antibodies,
respectively, followed by ISH with NPY, enkephalin, or GRPR probe as previ-
ously described (Liu et al., 2008). Three to five pairs of control and CKO mice
were used for quantitative analysis.
Neuron
VGLUT2 Is Required for Itch Suppression by PainStatistical Analyses of Pain and Itch Behaviors
For itching behaviors, the mean number of scratching bouts or wipes and SEM
during the period were calculated for each group. The difference between the
mutant and control group was subjected to a Student’s t test (two-sample
assuming unequal variance), with p < 0.05 considered significant. For acute
mechanical and heat pain, data were calculated as the average of two inde-
pendent tests performed on two consecutive days and subjected to the
Student’s t test. For CFA-induced inflammatory and SNI-induced neuropathic
pain, time-course measurements were analyzed by both analysis of variance
between groups (ANOVA) (within each group) and two-way repeated
ANOVA (R, R Development Core Team, Austria) (to compare groups), with
p < 0.05 accepted as statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/j.
neuron.2010.09.008.
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